Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (DE:42Z)
FRANKFURT:42Z
42Z Stock Chart & Stats
Day’s Range― - ―
52-Week Range€26.80 - €56.50
Previous CloseN/A
Volume0.00
Average Volume (3M)40.00
Market Cap
$7.00B
Enterprise Value€4.93B
Total Cash (Recent Filing)$2.14B
Total Debt (Recent Filing)$132.79M
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Nov 05, 2025EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding186,933,200
10 Day Avg. Volume36
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.98
Enterprise Value/Ebitda-5.58
Forecast
1Y Price Target
$60.75Price Target Upside68.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Clinical TrialsFeedback indicates daraxonrasib is changing the treatment paradigm in pancreatic cancer, further supporting the positive outlook for upcoming clinical trials.
Pipeline PotentialThe company's pipeline is seen as having best-in-class potential for selectively targeting mutant KRAS, compared to the current RAS(OFF) clinical landscape.
Regulatory ApprovalThe Phase 3 design provides an opportunity to seek approval for both daraxonrasib monotherapy and combination with chemotherapy.
Bears Say
Comparison With Standard TreatmentsFollow-up data from 2L+ PDAC daraxonrasib monotherapy demonstrated survival benefits for patients, clearing the bar set by GnP and supporting the potential success in first-line PDAC treatments.
Competitive LandscapeCompetitor's data showed an objective response rate slightly exceeding zoldonrasib’s in small patient numbers, limiting the comparison.
Revolution Medicines News
42Z FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was €26.80 and its highest was €56.50 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $7.00B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Nov 05, 2025 which is in 37 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Aug 06, 2025. The company reported -€1.115 earnings per share for the quarter, missing the consensus estimate of -€0.969 by -€0.146.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.2.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 186,933,200 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -€1.115 in its last earnings report, missing expectations of -€0.969. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in DE:42Z
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.75 (68.76% Upside)
$60.75 (68.76% Upside)
Blogger Sentiment
Neutral
DE:42Z Sentiment 50%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.13%
12-Months-Change
Fundamentals
Return on Equity
-46.61%
Trailing 12-Months
Asset Growth
34.35%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
42Z Company Deck
42Z Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with significant progress in clinical trials and strategic financial partnerships. However, increased expenses and dependency on regulatory approvals present challenges.View all DE:42Z earnings summaries42Z Stock 12 Month Forecast
Average Price Target
€60.75
▲(68.76% Upside)
Technical Analysis
Corcept Therapeutics
―
Ionis Pharmaceuticals
―
Blueprint Medicines
―
Legend Biotech
―
Vaxcyte
―
Options Prices
Currently, No data available
---